Ranbaxy Laboratories
Ranbaxy was an Indian multinational generic-drug company that became part of Sun Pharmaceutical Industries after a troubled acquisition and regulatory settlement.
Last updated November 4, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Ranbaxy Laboratories was an Indian multinational pharmaceutical company that became one of the country's best-known producers of generic medicines. Its commercial history began in 1937, when Ranbir Singh and Gurbax Singh established the business as a distributor for the Japanese drug company Shionogi. The name Ranbaxy was formed by combining elements of the founders' names. In 1952, Bhai Mohan Singh acquired the business from his cousins, and the company later developed from a distribution operation into a vertically integrated pharmaceutical manufacturer and international exporter. A major period of expansion followed the arrival of Bhai Mohan Singh's son, Parvinder Singh, in 1967. Under the Singh family's leadership, Ranbaxy invested in pharmaceutical research, manufacturing capacity and overseas commercialization. The company was incorporated in India in 1961 and became publicly traded in 1973. During the 1990s it established Ranbaxy Pharmaceuticals as an American affiliate and pursued the growing United States market for lower-cost generic drugs. The company also expanded across Europe, Latin America, Asia and Africa. By 2005, overseas markets represented approximately three quarters of its global sales, with the United States its largest individual market. Ranbaxy's portfolio included prescription generic medicines, active pharmaceutical ingredients and selected consumer-health products. Its competitive model depended on developing products after originator-drug patents expired, obtaining regulatory approvals in major markets and manufacturing at a scale that could support lower prices. The company achieved important commercial positions in products such as generic simvastatin and atorvastatin, although patent litigation and regulatory approval requirements were central to its business strategy. The company's growth was increasingly overshadowed by concerns about manufacturing controls, data integrity and regulatory compliance. Internal investigations in the early 2000s identified weaknesses in patient-safety reporting and plant record-keeping. Former employees' allegations and whistleblower disclosures later contributed to United States regulatory action against several Ranbaxy facilities. The US Food and Drug Administration found evidence that data submitted in drug applications had been falsified and that some manufacturing and testing practices did not meet applicable standards. Recalls and import restrictions further damaged the company's reputation. In 2008, Japan's Daiichi Sankyo acquired a controlling interest in Ranbaxy through a staged transaction. Malvinder Mohan Singh initially remained chief executive, but he left the role in 2009 and was replaced by Yugal Sikri. Daiichi Sankyo subsequently faced substantial financial and legal consequences after asserting that it had been misled about the extent of Ranbaxy's regulatory problems. In May 2013, Ranbaxy pleaded guilty in the United States to felony violations involving adulterated drugs and false statements to regulators and agreed to pay $500 million in criminal and civil penalties. On 7 April 2014, Sun Pharmaceutical Industries and Daiichi Sankyo announced an all-share transaction under which Sun would acquire the entire issued share capital of Ranbaxy. The transaction was valued at approximately $4 billion based on the announced terms, with Ranbaxy shareholders receiving Sun shares. The acquisition was completed later in 2014, bringing Ranbaxy under new management and ending its existence as an independent corporate entity. Ranbaxy's operations and product portfolio were subsequently integrated into Sun Pharma's global pharmaceutical business. The brand remains historically significant as an early Indian pharmaceutical exporter and as a prominent case in international debates about generic-drug quality, regulatory oversight and data integrity.
History
Ranbaxy's roots date to 1937, when Ranbir Singh and Gurbax Singh founded a business that distributed medicines for Japan's Shionogi. The company name combined portions of the founders' names. Bhai Mohan Singh bought the business from his cousins in 1952 and began building the enterprise into an Indian pharmaceutical company. The arrival of his son Parvinder Singh in 1967 coincided with an acceleration in scale, research activity and manufacturing development. Ranbaxy was incorporated in India in 1961 and listed publicly in 1973. Its long-term growth reflected the rise of India's pharmaceutical manufacturing sector and the global demand for less expensive alternatives to patented medicines. The company developed capabilities in formulation manufacturing and active pharmaceutical ingredients, then pursued registrations and commercial partnerships outside India. During the late 1990s it created Ranbaxy Pharmaceuticals as an American affiliate and worked with US businesswoman Agnes Varis to expand access to the United States generic-drug market. International sales became central to the business. In the twelve months ending 31 December 2005, reported global sales were $1.178 billion, with approximately 75 percent generated outside India. The United States accounted for about 28 percent of sales, Europe 17 percent, and Brazil, Russia and China collectively 29 percent. Patent litigation was an important part of the commercial environment. A 2005 ruling concerning Pfizer's Lipitor affected Ranbaxy's market expectations, while a later settlement allowed Ranbaxy to sell generic atorvastatin and an atorvastatin-amlodipine combination in the United States from November 2011. The FDA also granted Ranbaxy limited exclusivity for 80 mg generic simvastatin in 2006. At the same time, the company developed serious compliance problems. A 2003 audit by Lachman Consultant Services identified shortcomings in the patient-safety function and manufacturing records. Research and development director Rajinder Kumar resigned in 2004 after raising concerns about medicines that he believed had been approved using fraudulent testing. Dinesh Thakur, who had compiled information about the alleged data problems, also left and became a whistleblower. Their disclosures helped prompt later FDA scrutiny, including an import alert covering products associated with two Indian plants. Regulatory concerns intensified in 2009, when the FDA stopped reviewing Ranbaxy applications after investigators found evidence of falsified data at Paonta Sahib. Investigators also concluded that Ranbaxy had represented products as being made at a nearby, cleaner Batamandi facility when they had in fact been developed at Paonta Sahib. Additional recalls and plant findings followed. Pantoprazole batches were recalled in the Netherlands in 2012 because of impurities. Ranbaxy stopped production and recalled lots of atorvastatin after glass particles were found in bottles, and a later US recall involved bottles labeled as 10 mg that contained 20 mg tablets. FDA inspections also identified sanitation and manufacturing deficiencies at Mohali and significant testing and retesting violations at Toansa. Ownership changed during this period. Daiichi Sankyo acquired a 34.8 percent stake in June 2008 and completed a majority takeover later that year. Malvinder Mohan Singh initially remained chief executive but was removed in May 2009 amid concerns about quality control; Yugal Sikri, formerly associated with Novartis, replaced him. The new owner inherited a company whose regulatory exposure was more extensive than it had understood. In 2013, Ranbaxy admitted US felony violations concerning adulterated drugs and false statements and agreed to a $500 million settlement. The case involved products including antiretroviral medicines intended for HIV/AIDS treatment in Africa. Sun Pharmaceutical and Daiichi Sankyo announced the sale of Ranbaxy in April 2014. The all-share transaction provided Ranbaxy shareholders with Sun shares at a stated exchange ratio of 0.8 Sun share for each Ranbaxy share, while Daiichi Sankyo was expected to hold approximately 9 percent of Sun after completion. The acquisition brought new management and ended Ranbaxy as an independent company. In 2016, an international arbitration tribunal ordered former Ranbaxy shareholders to pay Daiichi Sankyo $525 million over alleged concealment of regulatory problems. Ranbaxy's history therefore combines the internationalization of Indian generic pharmaceuticals with a major cautionary episode concerning data integrity, manufacturing quality and the limits of due diligence in cross-border pharmaceutical acquisitions.
- 2014
Acquired by Sun Pharmaceutical
[1]Sun Pharmaceutical agreed to acquire Ranbaxy in an all-share transaction, after which Ranbaxy ceased to operate as an independent company.
- 2014
Sun Pharma acquisition
[4]Sun Pharmaceutical Industries agrees to acquire Ranbaxy from Daiichi Sankyo, and the transaction subsequently closes.
- 2013
US felony plea and settlement
[2]Ranbaxy pleaded guilty to multiple felony violations and agreed to pay $500 million in penalties and related payments.
- 2013
U.S. regulatory settlement
[3]Ranbaxy pleads guilty to U.S. felony charges and agrees to a settlement concerning adulterated drugs and misleading regulatory information.
- 2008
Daiichi Sankyo becomes majority owner
[1]Daiichi Sankyo completed its takeover of Ranbaxy after acquiring an initial controlling stake and additional shares.
- 2008
Daiichi Sankyo takes control
[1]Daiichi Sankyo acquires a controlling interest in Ranbaxy and adds the Indian generic-drug company to its group.
- 2006
US simvastatin exclusivity
[1]The FDA granted Ranbaxy 180-day exclusivity for the 80 mg strength of generic simvastatin.
- 1995
Brian Tempest becomes chief executive
[1]Brian Tempest begins a long period as chief executive during Ranbaxy's international expansion.
- 1973
Public listing
[1]The company became publicly traded.
- 1961
Incorporated in India
[1]Ranbaxy was incorporated as an Indian company.
Products and positioning
A large Indian generic-drug manufacturer positioned around affordable medicines, international regulatory approvals, broad manufacturing capacity and expansion into developed and emerging pharmaceutical markets. Its historical positioning was later severely weakened by quality-control, data-integrity and regulatory-compliance controversies. Historically positioned as an Indian multinational generic-pharmaceutical company combining low-cost manufacturing, branded generics, regulated-market approvals, and international distribution.
Cardiovascular and lipid-lowering medicine · 2011
Generic atorvastatin-amlodipine
Ranbaxy developed and marketed a generic version of Pfizer's cholesterol-lowering medicine Lipitor. Following a patent settlement, the company received US approval to launch the product after patent expiry in 2011. The product became one of the most commercially important examples of Ranbaxy's strategy of pursuing high-volume generic medicines in regulated markets. Ranbaxy obtained rights under its settlement with Pfizer to sell a generic version of Caduet, a combination of atorvastatin and amlodipine, in the United States. The product combined lipid management and blood-pressure treatment and formed part of the company's US generic portfolio.
Lipid-lowering medicine · 2006
Generic simvastatin
Ranbaxy supplied generic simvastatin, including the 80 mg strength for which the FDA granted the company a 180-day US exclusivity period in 2006. The product illustrates Ranbaxy's focus on patent-expiry opportunities involving widely prescribed branded medicines.
Anti-infective and HIV medicines
Antiretroviral medicines
Ranbaxy manufactured antiretroviral products, including medicines destined for HIV/AIDS treatment programs in Africa. Some products became part of the 2013 US criminal case concerning adulteration and the submission of misleading information to regulators.
Over-the-counter medicines and consumer health
Consumer-health products
Through Ranbaxy Global Consumer Health Care, the company also operated in consumer health and over-the-counter products. The division received an OTC Company of the Year award in 2011, although specific product names are not established in the supplied sources.
Generic pharmaceuticals
Generic prescription medicines
Ranbaxy's core business was the development, manufacture, registration, and sale of off-patent prescription medicines. Products were supplied in finished-dose forms across multiple therapeutic areas and sold through both the Indian branded-generic channel and international generic markets.
Pharmaceutical formulations
Branded generics
In India and selected overseas markets, Ranbaxy marketed generic medicines under product names supported by physician, pharmacy, and distribution networks. This branded-generic model was an important part of the company's domestic commercial identity.
Pharmaceutical ingredients
Active pharmaceutical ingredients
Ranbaxy also operated in active pharmaceutical ingredients and related pharmaceutical manufacturing activities, supporting its own finished products and commercial supply relationships.
Controversies
2016
Daiichi Sankyo arbitration award
The Singapore International Court of Arbitration ordered former Ranbaxy shareholders to pay Daiichi Sankyo $525 million after concluding that the severity of regulatory scrutiny had been intentionally misrepresented.
2014
FDA action against Toansa facility
The FDA prohibited the manufacture and distribution of active pharmaceutical ingredients from Toansa for FDA-regulated products after finding that failed materials and test results had been repeatedly retested without proper reporting or investigation.
2013
US felony convictions and $500 million settlement
Ranbaxy pleaded guilty to three felony violations of the Federal Food, Drug, and Cosmetic Act and four felony counts of knowingly making false statements to the FDA. The case involved adulterated medicines and misrepresented generic-drug data.
2013
Mohali manufacturing deficiencies
Reports described serious sanitation and manufacturing deficiencies at the Mohali facility, after which the FDA prohibited the site from manufacturing FDA-regulated drugs until compliance requirements were met.
2013
U.S. manufacturing and data-integrity case
The U.S. Department of Justice announced that Ranbaxy pleaded guilty to felony charges and agreed to a major settlement over the manufacture and distribution of adulterated drugs and false or misleading statements to the U.S. Food and Drug Administration. The case concerned quality systems, manufacturing conditions, testing, and regulatory data.
2012
Product recalls involving pantoprazole and atorvastatin
Pantoprazole batches were recalled in the Netherlands because of impurities. Ranbaxy also stopped production and recalled atorvastatin lots after glass particles were found in bottles; a labeling and dosage error later led to a US recall.
2009
FDA suspends review of Ranbaxy applications
The FDA halted reviews of Ranbaxy drug applications after investigators found evidence that data associated with the Paonta Sahib facility had been falsified and that another nearby facility had been presented as the source of products.
2004
Whistleblower allegations concerning fraudulent testing data
Rajinder Kumar resigned after raising concerns about medicines approved using allegedly fraudulent testing. Dinesh Thakur later became a whistleblower after compiling information about the alleged data manipulation.
2003
Audit identifies patient-safety and record-keeping weaknesses
An audit by Lachman Consultant Services reported that Ranbaxy's patient-safety function did not adequately investigate or report adverse-effect and ineffectiveness complaints and also identified poor manufacturing records.
Marketing campaigns
- 2011Generic Lipitor launch
United States
Ranbaxy prepared to commercialize generic atorvastatin and the atorvastatin-amlodipine combination following the expiry-related settlement of its dispute with Pfizer.
Outcome. The products received US approval and represented a major patent-expiry opportunity for the company.
- 1990US generic-market expansion
United States
Ranbaxy expanded its presence in the United States through its American affiliate, Ranbaxy Pharmaceuticals, targeting demand for lower-cost generic medicines.
Outcome. The United States became Ranbaxy's largest individual overseas market, but the business later faced extensive FDA scrutiny.
Brand decisions
2014
Sell Ranbaxy to Sun PharmaceuticalM&ABackground
Daiichi Sankyo sought an exit after Ranbaxy faced significant regulatory, compliance, and operational challenges in key markets.
Action taken
Sun Pharmaceutical agreed to acquire all of Ranbaxy in an all-share transaction. Ranbaxy shareholders were to receive 0.8 Sun shares for each Ranbaxy share.
Aftermath
Sun obtained Ranbaxy's operations and portfolio, and Ranbaxy ceased to exist as an independent company. Daiichi Sankyo was expected to hold approximately 9 percent of Sun after completion.
Announced transaction value. Approximately $4 billion (2014)
2013
Enter US criminal settlementOtherBackground
US authorities alleged that Ranbaxy manufactured adulterated drugs and submitted false information about generic-drug testing and manufacturing.
Action taken
Ranbaxy pleaded guilty to seven felony counts and agreed to pay $500 million in penalties and related payments.
Aftermath
The settlement intensified regulatory restrictions and contributed to the company's loss of independence and reputational damage.
Criminal and civil monetary settlement. $500 million (2013)
2011
Launch generic atorvastatin in the United StatesProduct launchBackground
Ranbaxy had settled its patent dispute with Pfizer over Lipitor and Caduet-related products.
Action taken
Ranbaxy obtained FDA approval to market generic atorvastatin after the relevant patent protection expired.
Aftermath
The launch made a major branded cholesterol medicine available as a generic product, while Ranbaxy continued to face broader compliance scrutiny.
2008
Sell control to Daiichi SankyoM&ABackground
Ranbaxy was pursuing international growth while seeking a strategic ownership structure capable of supporting its global pharmaceutical operations.
Action taken
Daiichi Sankyo acquired an initial 34.8 percent stake from Malvinder Mohan Singh and later increased its holding to become the majority owner. Daiichi Sankyo acquired a controlling interest in Ranbaxy and became its controlling shareholder.
Aftermath
Daiichi Sankyo installed new leadership but later alleged that the severity of Ranbaxy's regulatory problems had been concealed. Ranbaxy operated within the Daiichi Sankyo group, but later regulatory problems and the resulting commercial impact contributed to a subsequent sale.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ranbaxy-laboratories · Editorial policy · How profiles are compiled